Capitulo 2 farmacocinética

Understanding Pharmacokinetics

Overview of Pharmacokinetics

• The dynamic pharmacokinetic processes include absorption, distribution, metabolism, and elimination of drugs.

• To effectively control the therapeutic action of drugs in the human body, it is crucial to understand how much drug reaches its site of action and when this occurs.

Key Processes in Drug Action

• The processes involved in pharmacokinetics are essential for understanding drug behavior within the body.

• Successful therapeutic outcomes depend on effective drug delivery while minimizing adverse pharmacological effects.

Factors Influencing Drug Transfer

• Physical and chemical factors play a significant role in drug transfer across cellular membranes.

• Knowledge of mechanisms that allow drugs to cross membranes, along with the physicochemical properties of both molecules and membranes, is vital for understanding drug disposition.

Characteristics Affecting Drug Movement

• Key characteristics predicting a drug's movement and availability at action sites include molecular size and shape, ionization degree, lipid solubility, and protein binding affinity.

• Most drugs must traverse multiple cell membranes to reach their target site.

Membrane Structure and Function

• Cellular barriers can range from single epithelial cell layers to complex structures like skin; however, plasma membranes are the most common barrier for drug distribution.

• Plasma membranes consist of a lipid bilayer with hydrophobic interiors formed by carbohydrate chains oriented inward.

Lipid Bilayer Dynamics

• Individual lipid molecules within the bilayer can move laterally and organize with cholesterol to maintain membrane integrity.

• Properties such as fluidity, flexibility, organization, electrical resistance, and relative impermeability to polar molecules are critical for membrane function.

Role of Membrane Proteins

• Membrane proteins act as receptors or transporters that facilitate signaling pathways; they serve as targets for medication action.

• Contrary to earlier beliefs about disordered protein arrangements in membranes, current understanding indicates that these proteins are highly organized within specific domains.

Permeability Considerations

• Cell membranes exhibit relative permeability to water through diffusion influenced by hydrostatic or osmotic differences across the membrane.

• However, large polar drug-protein complexes cannot easily pass through these barriers due to their size.

Transport Mechanisms

• Generally, only free (unbound) drugs can move across cell membranes; bound complexes may act as inactive reservoirs affecting therapeutic efficacy.

Intercellular Transport Limitations

• Intercellular transport is sufficient for movement through most capillaries but varies based on tissue type.

• Certain tissues have tight junction intercellular connections limiting transport capabilities significantly.

Special Cases: CNS Capillaries

• Capillaries in the central nervous system possess unique epithelial junctional structures that restrict transport further.

Molecular Size Constraints

• While small water-soluble substances can be transported via mass flow of water , larger solutes face limitations if their molecular weight exceeds 100–200 Daltons.

Passive Transport Mechanisms

Passive Diffusion Process

• Drugs typically cross membranes via passive diffusion following concentration gradients due to their solubility in lipid bilayers.

Factors Affecting Passive Diffusion Rate

• The rate of passive transfer correlates directly with concentration gradient magnitude across the membrane , lipophilicity coefficient ,and surface area contact between drug and membrane .

Influence of Lipophilicity on Diffusion Speed

Equilibrium and Drug Distribution

Understanding Equilibrium in Drug Concentration

• Once equilibrium is reached, the concentration of free drug is equal on both sides of the membrane, provided the drug is not an electrolyte.

Ionization and pH Effects

• For ionic compounds, equilibrium concentrations depend on the electrochemical gradient for ions and pH differences across the membrane, which unevenly modify ionization states.

• Most drugs are weak acids or bases in solution, existing in either ionized or non-ionized forms.

Membrane Permeability

• Non-ionized molecules are typically lipophilic and can diffuse through cell membranes.

• Conversely, ionized molecules cannot penetrate lipid membranes due to their charge and solubility; permeability relates to membrane electrical resistance.

Impact of pH on Drug Distribution

• The transmembrane distribution of weak electrolytes often depends on the pH gradient between both sides of the membrane.

• The pH at which half of a weak electrolyte drug exists in its ionized form illustrates how pH affects drug distribution.

Example: Weak Acid Partitioning

• An example shows partitioning between plasma (pH 7.4) and gastric juice (pH 1).

• The permeable form is typically the non-ionized lipophilic version of acidic substances.

Ionization Ratios and Drug Accumulation

Calculating Ionization Ratios

• In gastric juice, the ratio of non-ionized to ionized drug is calculated as 1:0:0:1 based on specific conditions shown in Figure 2.3.

Equilibrium Concentrations

• If equilibrium were achieved, total concentration ratios between plasma and gastric juice would also reflect this calculation.

Behavior of Weak Bases

• A weak base with a specific pKa will show different predominant species at varying pH levels as illustrated by thick horizontal lines in Figure 2.3.

Accumulation Based on Membrane Side

• At equilibrium, acidic drugs accumulate on more alkaline sides while basic drugs accumulate on more acidic sides.

Common Ionizable Groups in Drugs

Characteristics of Ionizable Groups

• Common ionizable groups include carboxylic acids (pKa ~4.5), primary amines (pKa ~9), with many compounds having multiple ionizable groups leading to varied pKa values.

Implications for Pharmacology

• Some drugs contain permanently charged quaternary amines; this impacts their pharmacological effects such as reduced sedation from second-generation antihistamines compared to first-generation ones due to lower lipophilicity at physiological pH (~7).

Urinary Excretion Influences

Variability in Urinary pH

• Urinary pH can range widely from 4.5 to 8 affecting excretion rates for weak acids and bases based on their ionization state.

Modifying Urine for Enhanced Excretion

• Altering urinary pH can enhance elimination; alkaline urine favors excretion of weak acids while acidic urine favors excretion of weak bases.

Practical Application

• Administering sodium bicarbonate raises urinary pH promoting excretion of weak acids like acetylsalicylic acid (~3).

Transport Mechanisms Across Membranes

Passive vs Active Transport Dynamics

• Establishment of concentration gradients for weak electrolytes across membranes occurs passively without active transport systems but requires preferential permeability towards one form.

Role of Diffusion

• Passive diffusion through bilayers predominates in drug elimination processes although transporter-mediated mechanisms may also play significant roles.

Characteristics of Active Transport

Active Transport Mechanisms in Pharmacology

Overview of Active Transport and Digoxin

• La NAMAS, Camás AdPasa, es un mecanismo de transporte activo clave en el tratamiento de la insuficiencia cardíaca con digoxina.

Secondary Active Transport

• El transporte activo secundario utiliza energía electroquímica para mover moléculas contra su gradiente de concentración, como lo hace la proteína de intercambio namás que exporta sodio y mantiene niveles bajos en las células.

Diffusion and Passive Transport

• La difusión facilitada describe el transporte a través de un portador sin gasto energético, siguiendo el gradiente electroquímico; por ejemplo, la glucosa entra en las células musculares mediante GLUT4.

Importance of Selective Transporters

• Los transportadores son cruciales para el transporte eficiente de compuestos endógenos y pueden ser selectivos según la estructura del fármaco.

Role of P-glycoprotein in Drug Absorption

• La glucoproteína P-glycoprotein (MDR1) limita la absorción oral al exportar fármacos hacia el aparato digestivo tras su difusión pasiva.

• Esta misma proteína puede conferir resistencia a ciertos medicamentos utilizados en quimioterapia.

Biodisponibilidad y Metabolismo Hepático

Concepto de Biodisponibilidad

• La biodisponibilidad se refiere al grado en que un fármaco llega a su sitio de acción o líquido biológico desde su administración.

Proceso de Absorción del Fármaco

• Para presentaciones sólidas como tabletas o cápsulas, es necesario que se disuelvan primero para permitir la absorción del fármaco.

Efecto del Hígado en Disponibilidad del Fármaco

• Tras la absorción, los fármacos pasan por el hígado donde pueden sufrir metabolismo o excreción antes de llegar a la circulación general.

Impacto del Efecto de Primer Paso

• Un alto metabolismo hepático puede reducir significativamente la biodisponibilidad debido al efecto conocido como "primer paso".

Vías de Administración: Comparación Oral vs Parenteral

Elección de Vía Administrativa

• Los médicos deben considerar las ventajas y desventajas al elegir una vía administrativa para un compuesto terapéutico.

Ventajas y Desventajas de Vía Oral

• La vía oral es común por ser inocua y conveniente; sin embargo, algunos fármacos no se absorben bien debido a sus características físicas.

Limitaciones Específicas

• Factores como solubilidad en agua, irritación gastrointestinal o interacciones con alimentos pueden afectar negativamente la absorción.

Metabolismo Intestinal

Advantages and Disadvantages of Parenteral Drug Administration

Advantages of Parenteral Administration

• La inyección parenteral de ciertos fármacos ofrece ventajas sobre la administración oral, como una disponibilidad más rápida y predecible.

• En casos críticos, como el tratamiento con anticuerpos monoclonales (ej. inflíxima para artritis reumatoide), es indispensable la vía parenteral para suministrar la forma activa del fármaco.

• La administración por inyección permite una dosificación más precisa y eficaz en situaciones de urgencia.

• Es esencial en pacientes inconscientes o que no pueden retener medicamentos por vía oral.

Desventajas de Parenteral Administration

• Las inyecciones requieren asepsia adecuada, especialmente en tratamientos prolongados; algunas son dolorosas y difíciles de autoadministrar.

Factors Influencing Oral Drug Absorption

Mechanisms of Absorption

• La absorción depende del estado físico del fármaco (solución, suspensión o sólido), su hidrosolubilidad y concentración en el sitio de absorción.

• Para medicamentos sólidos, la rapidez de disolución puede limitar su absorción, especialmente si tienen baja solubilidad.

pH and Absorption

• La mayoría de los fármacos se absorben a través de mecanismos pasivos; mayor absorción ocurre cuando están en forma no ionizada y lipofílica.

• Los ácidos débiles se absorben mejor en el estómago (pH 1 a 2), mientras que las bases débiles lo hacen mejor en el duodeno (pH 3 a 6).

Surface Area Considerations

• Aunque el estómago tiene un área superficial pequeña debido a su revestimiento mucoso grueso, el intestino delgado tiene vellosidades que aumentan significativamente su superficie para la absorción.

Gastric Emptying and Its Impact on Drug Absorption

Factors Affecting Gastric Emptying

• La actividad motora gástrica y la velocidad de vaciamiento son controladas por mecanismos neuronales influenciados por varios factores como contenido calórico, volumen y temperatura del líquido ingerido.

Gender Differences in Gastric Emptying

• En mujeres premenopáusicas o aquellas bajo tratamiento hormonal con estrógenos, el vaciamiento gástrico es más lento comparado con hombres.

Enteric Coatings and Controlled Release Formulations

Enteric Coatings for Sensitive Drugs

• Fármacos sensibles a secreciones gástricas se administran con recubrimientos entericos que impiden su disolución en ambientes ácidos.

Benefits of Controlled Release Formulations

Pharmacological Release Mechanisms

Controlled Release vs. Immediate Release

• Controlled release formulations can lead to more pronounced effects compared to immediate-release preparations, but failures in formulation may cause rapid drug release and significant side effects due to excessive doses.

• Controlled release forms of certain drugs, like oxycodone, can lead to misuse; thus, they should only be prescribed when specific advantages are demonstrated.

Absorption Characteristics

Sublingual Absorption

• Nitrogliserin is effective sublingually due to its high liposolubility and non-ionic nature, allowing for rapid absorption into the bloodstream.

Transdermal Absorption

• The absorption of drugs through the skin depends on their liposolubility and the surface area applied; hydrated skin enhances permeability compared to dry skin.

• Increasingly popular transdermal patches include nicotine for smoking cessation and nitroglycerin for angina treatment.

Rectal Administration Insights

• Rectal administration bypasses first-pass metabolism by the liver but often results in irregular absorption and potential irritation of rectal mucosa.

• Utilizing micro-spheres that adhere to mucus may improve drug delivery via this route.

Parenteral Administration Dynamics

Intramuscular Injection

• In intramuscular injections, drug absorption occurs through simple diffusion following concentration gradients between the drug depot and plasma.

Intravenous Administration Benefits

• Intravenous administration ensures complete and rapid bioavailability with controlled delivery of medications directly into circulation.

Administration of Medications: Advantages and Disadvantages

Overview of Administration Routes

• There are advantages and disadvantages to different routes of medication administration.

• Adverse reactions can occur due to high concentrations of drugs in plasma and tissues.

Specific Administration Techniques

• In certain therapeutic circumstances, rapid administration of a small volume of medication is recommended.

• An example includes the immediate administration of a thrombolytic agent after an acute myocardial infarction, while slow administration is advised in other cases.

Monitoring Patient Response

• Antibiotics and intravenous solutions require careful monitoring after intravenous drug administration.

• Once a drug is injected intravenously, there is no turning back; thus, patient response must be closely observed.

Subcutaneous Administration Insights

Absorption Characteristics

• After subcutaneous injection, the absorption rate is generally consistent and slow enough to provide sustained effects.

• The absorption period can be intentionally modified based on factors like particle size, protein complexes, and pH for short (3–6 hours), intermediate (10–18 hours), or prolonged (18–24 hours) action.

Enhancing Absorption

• Incorporating a vasoconstrictor into the subcutaneous solution can prolong drug absorption.

• For instance, local anesthetics like lidocaine often contain adrenaline to enhance their effectiveness.

Intramuscular Injection Considerations

Factors Affecting Absorption Rate

• The speed of absorption from intramuscular injections depends on circulation at the injection site.

• Local heat application or massage can regulate this absorption rate.

Variability in Absorption Rates

• Insulin absorption tends to be faster when injected into the arm or abdominal wall compared to the thigh due to increased circulation during exercise.

Intra-Arterial and Intra-Spinal Administration

Targeted Drug Delivery

• Direct intra-arterial injections may limit drug effects to specific organs or tissues, such as tumors in hepatic regions or head/neck areas.

Central Nervous System Applications

• Intra-spinal injections target the central nervous system for rapid local effects in conditions like meningitis through direct delivery into the cerebrospinal fluid.

Absorption and Administration of Drugs

Mechanisms of Drug Absorption

• The product reaches circulation quickly due to the large area of its pulmonary absorption.

• Chapter 19 outlines principles governing the absorption and excretion of anesthetics and other therapeutic gases.

• It is possible to aerosolize medication solutions, creating fine droplets for administration.

Advantages of Pulmonary Administration

• Key benefits include almost instantaneous drug absorption into the bloodstream, bypassing first-pass metabolism in the liver, and local application for respiratory conditions.

• For instance, drugs can be administered via this method for treating allergic rhinitis or bronchial asthma as discussed in Chapter 36.

Local vs. Systemic Effects

• Pulmonary absorption also serves as a significant entry point for illicit drugs and various environmental toxins.

• Inhalation may lead to local and systemic reactions; medications are applied topically on mucous membranes such as conjunctiva, nasopharynx, buccopharynx, vagina, colon, urethra, and bladder for localized effects.

Rapid Absorption through Mucous Membranes

• Some applications aim for generalized absorption; an example is synthetic antidiuretic hormone applied to nasal mucosa.

• Mucosal absorption occurs rapidly; local anesthetics can sometimes absorb so quickly that they cause systemic toxic effects.

Ocular Drug Delivery Systems

• Drugs absorbed through ocular drainage avoid hepatic metabolism; thus, topical eye drops can lead to undesirable systemic effects.

• For localized effects via ocular delivery, drugs must penetrate the cornea; infections or trauma can accelerate this process.

Innovations in Drug Delivery

Prolonged Action Systems

• Systems like ointments are useful in ophthalmic treatments by prolonging action duration.

• Ocular implants (e.g., pilocarpine inclusions for glaucoma treatment) provide continuous small doses with minimal loss through ocular drainage.

Advanced Drug Release Methods

• New drug release methods involve endoprotheses and devices that minimize contact with general circulation while delivering medication locally.

Enhancing Therapeutic Index

• Side effects from various compounds can be significantly reduced when combined with vehicles that modify their distribution.

• An example includes calicheamicin combined with antibodies targeting specific leukemia cell antigens to improve therapeutic index.

Bioequivalence Concerns

Understanding Bioequivalence

• Two pharmacologically equivalent substances are considered bioequivalent if their active ingredient's availability does not differ significantly under similar conditions.

Historical Context of Bioavailability

• Past differences in bioavailability were noted among products from different manufacturers or even within batches from a single manufacturer.

Specific Case Studies

• Such discrepancies were particularly observed in oral formulations of certain poorly soluble antibiotics like metronidazole.

• Initially, generic forms lacked bioequivalence because manufacturers could not replicate original compression processes facilitating drug absorption.

Factors Affecting Absorption

• Variations in crystal form, particle size, and other physical characteristics not strictly regulated during formulation affect disintegration speed and dissolution rate impacting overall absorption.

Discussion on Generic Drugs and Their Therapeutic Effects

Lack of Clinical Studies

• There are no prospective clinical studies demonstrating that FDA-approved generic drugs produce different therapeutic effects, despite anecdotal reports suggesting non-equivalence.

Concerns Among Physicians

• The legitimate concerns of physicians regarding the economic implications of prescribing generic drugs will continue to be an active topic of discussion.

Prescription Practices

• The prescription practices for patent generic drugs are examined in detail concerning drug nomenclature and the selection of names in medical prescriptions.

Pharmacokinetics: Drug Distribution Mechanisms

Initial Drug Distribution

• Initially, a drug is distributed within interstitial fluids and intracellular spaces, influenced by various physiological factors and the specific physicochemical properties of each medication.

Factors Affecting Tissue Distribution

• Key elements governing the rate at which drugs reach tissues include cardiac output, regional blood flow, capillary permeability, and volume distribution.

Phases of Drug Distribution

• The second phase of distribution can take minutes to hours for drug concentration in tissues to equilibrate with blood levels. This phase typically involves a larger fraction of body mass compared to the initial phase.

Tissue Permeability and Drug Diffusion

Rapid Diffusion Characteristics

• Except for certain areas like the brain, drug diffusion into interstitial fluid occurs rapidly due to the high permeability nature of capillary endothelial membranes.

Role of Lipophilicity

• Tissue distribution depends on the partition coefficient between blood and specific tissues; lipophilicity is a crucial determinant along with pH gradients between intracellular and extracellular fluids for weak base drugs.

Protein Binding Dynamics

Plasma Protein Binding

• Drugs bind to plasma proteins such as albumin; acidic drugs often bind more effectively than basic ones. Non-specific binding is less common but can occur through covalent bonds with reactive medications.

Impact on Free Drug Concentration

• The fraction of drug bound in plasma depends on its concentration relative to binding sites. Low concentrations lead to binding based on site availability; high concentrations depend on both site numbers and drug concentration.

Clinical Implications of Protein Binding Changes

Disease Impact on Binding

• Conditions like hypoalbuminemia from severe illness or nephrotic syndrome reduce protein binding, increasing free fractions. Acute-phase reactions from cancer or chronic diseases can elevate glycoprotein levels affecting basic drug binding.

Importance for High Clearance Drugs

Pharmacokinetics and Drug Binding

Drug Binding and Plasma Protein Interaction

• Significant alterations in drug concentration occur only with changes in free drug entry or elimination due to metabolism or active transport.

• A common issue arises from the competition of drugs for plasma protein binding sites, leading to misinterpretation of measured plasma drug concentrations, as most clinical studies do not differentiate between free and protein-bound drugs.

• The binding of a drug to plasma proteins reduces its concentration in tissues and at the site of action since only free drugs can equilibrate across membranes.

• Once equilibrium is achieved, the concentration of free and active drug in interstitial fluid matches that in plasma, except when transporter-mediated processes are involved.

• Plasma protein binding also limits glomerular filtration of the drug; however, it does not restrict renal tubular secretion or biotransformation.

Drug Metabolism and Elimination

• While plasma protein binding does not limit tubular secretion or biotransformation, these processes decrease free drug concentration, allowing for re-establishment of equilibrium between free and bound forms.

• Binding to plasma proteins also affects drug transport and metabolism; exceptions exist where specific conditions allow for increased elimination rates exceeding circulation levels.

Tissue Accumulation

• During prolonged administration of certain drugs like quinine, tissue concentrations may be significantly higher than those found in blood due to accumulation via active transport or binding mechanisms.

• Tissue binding typically occurs with cellular components such as proteins or phospholipids and is usually reversible. This creates a reservoir effect prolonging medication action at distant sites through circulation.

Adverse Effects from Tissue Accumulation

• Local adverse effects can arise from tissue accumulation; for instance, aminoglycoside gentamicin can accumulate in kidneys and vestibular systems causing toxicity.

Fat as a Drug Reservoir

• Body fat can constitute up to 50% lipid content; even during malnutrition, it remains about 10% body weight. Thus, fat serves as an important reservoir for lipophilic drugs.

• For example, up to 70% of thiopental (a highly lipophilic anesthetic) may reside in body fat three hours post-administration while blood concentrations are minimal without measurable anesthetic effects.

Bone as a Slow Release Depot

• Bone can absorb toxic agents like lead or radium into its crystalline structure, serving as a slow-release depot into the bloodstream long after exposure has ceased.

• This creates a vicious cycle where increased exposure leads to slower elimination rates due to local destruction reducing blood flow around bone tissue.

Therapeutic Advantages of Bone Adsorption

• The adsorption of drugs onto bone crystals offers therapeutic benefits for treating osteoporosis.

• Bisphosphonates like sodium etidronate strongly bind to hydroxyapatite crystals within mineralized bone matrix but resist degradation by pyrophosphatases unlike natural bisphosphonates.

Redistribution Dynamics

• Redistribution refers to the movement of drugs from their site of action towards other tissues. Highly lipophilic substances administered rapidly via IV injection often see redistribution contributing significantly to termination effects.

Example: Thiopental Anesthesia

• Thiopental acts quickly upon intravenous administration due to high cerebral blood flow reaching peak concentrations within minutes post-injection.

Anesthesia and Drug Distribution in the Central Nervous System

Anesthesia Onset and Duration

• Anesthesia begins and concludes rapidly, indicating a brief duration of action.

• The onset and offset of anesthesia are directly related to the concentration of the drug in the brain.

Blood-Brain Barrier Dynamics

• The central nervous system (CNS) is protected by cerebrospinal fluid (CSF).

• Drug distribution from blood to CNS is unique due to tight junctions in endothelial cells of brain capillaries.

• Drug penetration into brain tissue relies on transcellular transport rather than paracellular pathways.

Characteristics of Endothelial Cells

• Unique features of endothelial cells and glial cells form the blood-brain barrier (BBB).

• In the choroid plexus, a similar barrier exists between blood and CSF, formed by epithelial cell tight junctions.

Lipophilicity's Role in Drug Penetration

• Liposolubility significantly influences drug uptake by the brain; more lipophilic drugs cross the BBB more easily.

• This principle is applied in drug design; for instance, second-generation antihistamines like loratadine have lower CNS concentrations compared to diphenhydramine, resulting in less sedation.

Transport Mechanisms Across Barriers

• Some drugs access the CNS via specific transporters that typically facilitate nutrient transport from blood to brain.

• Membrane transporters play a crucial role at the BBB, expelling various chemically distinct drugs from endothelial cells.

Key Transport Proteins

• Important transport proteins include P-glycoprotein (P-gp), encoded by MDR1, which restrict drug access to tissues expressing these efflux pumps.

• P-gp and other ATP-binding cassette (ABC) transporters affect a wide range of drugs with different structures.

Implications for Drug Absorption and Elimination

• The expression of efflux transporters explains limited drug access to the brain and other tissues like testes despite adequate blood flow.

• This situation is observed with protease inhibitors such as lopinavir that lack central effects despite systemic activity.

Active Secretion Mechanisms

• Certain efflux transporters actively secrete drugs from CSF back into blood at sites like the choroid plexus.

Effects of Inflammation on BBB Permeability

• Generally, BBB function remains intact; however, meningeal or encephalic inflammation can increase local permeability.

Drug Transfer Across Placenta

Factors Influencing Placental Transfer

• Medications administered before delivery can adversely affect newborn health; this includes common practices during preterm labor treatment.

• General factors affecting drug transfer through placenta include lipophilicity, protein binding affinity, and ionization degree of weak acids/bases.

Fetal Plasma Characteristics

• Fetal plasma has a slightly more acidic pH than maternal plasma.

Transport Proteins in Placenta

• Similar to the BBB, placental P-glycoprotein (P-gp), along with other transporters restrict exposure between fetus and potentially harmful substances.

Misconceptions About Placental Barrier

• The belief that placenta serves as an absolute barrier for all drugs is misleading since several transporters facilitate entry into fetal circulation.

Drug Excretion Processes

Excretion Pathways

• Drugs are either excreted unchanged or metabolized into metabolites before elimination from body systems.

Efficiency Based on Compound Properties

• Polar compounds are eliminated more effectively than highly lipophilic substances due to their metabolic conversion into polar derivatives.

Renal Excretion Importance

Excretion of Drugs and Metabolites

Mechanisms of Drug Excretion

• The substances eliminated in the enterohepatic circulation (SES) primarily consist of unabsorbed oral medications or metabolites excreted in bile, which are secreted directly into the digestive tract and thus not reabsorbed.

• The excretion of drugs in breast milk is significant, not due to the quantity but because it can lead to undesirable pharmacological effects in nursing infants (Winschie-Wayner, 2009).

• Pulmonary excretion plays a crucial role mainly for the elimination of anesthetic gases.

Renal Excretion Processes

• Renal excretion involves glomerular filtration, active tubular secretion, and passive tubular reabsorption. Changes in overall kidney function affect these processes similarly.

• Even healthy individuals exhibit variability in renal function.

• In newborns, renal function is reduced relative to body volume but matures rapidly within the first months of life.

Factors Influencing Drug Penetration and Reabsorption

• During maturity, renal function declines gradually at approximately 1% per year; significant functional deterioration may occur in some elderly individuals.

• The amount of drugs entering tubules depends on glomerular filtration rate and drug binding to plasma proteins; only free (unbound) drug is filtered.

• Active tubular secretion mediated by transporters can also contribute drugs from tubular fluid back into circulation.

Transport Mechanisms in Renal Tubules

• Transporters like P-glycoprotein and MRP2 facilitate the secretion of anionic amphipathic compounds and conjugated metabolites such as glucuronides and sulfates from proximal renal tubules.

• Solute transporters selective for organic cations participate actively in secreting organic bases.

Reabsorption Dynamics

• Membrane transporters located distally within renal tubules are responsible for actively reabsorbing drugs back into systemic circulation.

• A significant portion of this reabsorption occurs via ionic diffusion rather than active transport mechanisms.

Influence of pH on Drug Excretion

• Weak acids and bases that are non-ionized experience net passive reabsorption across proximal and distal tubules based on urine pH levels.

• Alkaline urine promotes rapid excretion of weak acids due to increased ionization, reducing passive reabsorption rates. Conversely, acidic urine decreases ionization leading to reduced drug excretion.

Clinical Implications

• Altering urinary pH can be utilized therapeutically to accelerate the excretion process during cases of drug overdose or poisoning by either alkalinizing or acidifying urine.

Hepatic Recycling Effects

• Hepatocytes possess similar transporters as those found in kidneys that actively secrete drugs and their metabolites into bile.

• Enterocytes express secretory transporters allowing direct secretion from general circulation into intestinal lumen during digestion.

Example Applications

Esetimiba: A New Class of Cholesterol-Reducing Drugs

Mechanism of Action

• Esetimiba is the first in a new class of drugs that specifically reduce intestinal absorption of cholesterol (Lipca, 2003).

• The drug is absorbed in intestinal epithelial cells and interferes with the sterol transport system.

• It prevents the transport of free cholesterol and plant sterols from the intestinal lumen to the cell.

• Esetimiba is rapidly absorbed and glucuronidated within intestinal cells before being secreted into the bloodstream.

• The liver avidly absorbs esitimiba from portal blood and excretes it into bile, reducing its concentration in peripheral blood.

Excretion Pathways

• The glucuronide conjugate is hydrolyzed and absorbed, effectively inhibiting sterol absorption.

• Hepatic recycling leads to a half-life in the body of approximately 20 hours.

• A primary benefit is a reduction in low-density lipoproteins (LDL), as noted by Bocavillson (2009).

Drug Elimination

• Excretion through other pathways depends on diffusion of non-ionized lipophilic drugs across epithelial cells influenced by pH.

• Drugs excreted in saliva can be swallowed, with concentrations often mirroring those found in plasma.

• Saliva may serve as a useful biological fluid for measuring drug concentrations when obtaining blood samples is difficult.

Maternal Considerations

• Similar principles apply to drug excretion in breast milk; this milk's acidity affects compound concentration compared to plasma.

• Non-electrolytic substances like ethanol easily reach breast milk at plasma-equivalent concentrations regardless of pH.

Pharmacokinetics Insights

• When administering medications to breastfeeding women, it's crucial to consider potential exposure for infants through milk or metabolites.

• During atenolol treatment, significant exposure occurs for nursing infants (Lee, 2003).

Metabolism and Biotransformation of Drugs

Lipophilicity and Drug Elimination

• Lipophilic characteristics facilitate drug passage through biological membranes but hinder elimination from the body.

• Approximately 25% to 30% of administered drugs are eliminated intact.

Importance of Metabolism

• Most therapeutic agents are lipophilic compounds filtered by glomeruli but largely reabsorbed during renal tubular passage.

• Metabolism converts drugs into more hydrophilic metabolites essential for their elimination and cessation of biological activity.

Biotransformation Reactions

• Biotransformation reactions typically yield inactive polar metabolites that are easily excreted.

• However, some metabolic processes produce biologically active or toxic metabolites.

Enzymatic Systems Role

• Many enzymatic systems responsible for converting drugs into inactive metabolites also generate active metabolites from endogenous compounds during steroid biosynthesis.

Pharmacogenetics: Tailoring Treatments

Understanding Individual Variability

• Knowledge about drug metabolism has led to pharmacogenetics—a discipline aimed at understanding specific enzyme expression and activity variations among individuals.

• This understanding allows physicians to adjust treatments—especially chemotherapy—to improve therapeutic outcomes while minimizing toxicity risks (Budile & Landhones, 2009).

Classification of Metabolic Reactions

• Drug metabolism reactions are classified as phase I functionalization reactions or phase II synthetic conjugation reactions.

• Phase I reactions expose functional groups on original compounds; they generally lead to loss of pharmacological activity but can retain potency in rare cases.

Prodrugs Concept

• In rare instances, metabolism results in altered pharmacological activity; prodrugs are inactive compounds designed to enhance active species reaching their action sites.

• Prodrugs convert quickly into biologically active metabolites often via hydrolysis or amid bond cleavage.

Clinical Applications

Biotransformation and Pharmacokinetics

Biotransformation of Drugs

• Enalapril is relatively inactive until converted by esterases into its active form, angiotensin-converting enzyme (ACE) inhibitor.

• If not quickly excreted in urine, biotransformation products react with endogenous compounds to form highly soluble conjugates.

• Phase 2 conjugation reactions result in covalent bonds between functional groups on the original compound or phase I metabolite and endogenous derivatives like glucuronic acid or sulfate.

• These strongly polar conjugates are usually inactive and rapidly excreted via urine and feces.

• An example of an active conjugate is the 6-glucuronide metabolite of morphine, which is more potent than the original compound.

Metabolic Activity Locations

• The enzymatic systems involved in drug biotransformation primarily reside in the liver, although any examined tissue exhibits some metabolic activity.

• The digestive system, kidneys, and lungs also possess notable metabolic potential.

• After oral administration of a drug, much of the dose undergoes metabolic deactivation in intestinal epithelium or liver before reaching systemic circulation.

• This first-pass metabolism significantly limits the oral availability of highly metabolized drugs.

Cellular Drug Metabolism

• Most metabolic activity occurs within cells' endoplasmic reticulum and cytosol; however, drug biotransformation can also occur in mitochondria and plasma membranes.

• Enzymatic systems for phase I reactions predominantly operate in the endoplasmic reticulum while phase II conjugation enzymes are mainly cytosolic.

Cytochrome P450 Enzymes

• Drugs undergoing phase I biotransformation often get sequentially conjugated at the same site within the cytosolic fraction of that cell.

• Key players in these biotransformation reactions include isoforms of cytochrome P450 and various transferases.

• Detailed descriptions of these enzyme families, their catalytic roles, and involvement in drug metabolism as well as adverse pharmacological responses are covered extensively in Chapter 6.

Clinical Pharmacokinetics Principles

• A fundamental principle of clinical pharmacokinetics is establishing a relationship between a drug's pharmacological effects and its available concentration (e.g., blood or plasma).

• There may be a straightforward relationship between pharmacological effect and plasma concentration; however, it can be impractical to systematically measure concentrations for therapeutic monitoring for some drugs.

Concentration Effects

• In most cases, as illustrated by Figure 2.1, drug concentration at action sites depends on its concentration within systemic circulation.

• Resulting pharmacological effects can include desired clinical outcomes, toxic effects, or sometimes unrelated side effects.

Importance of Pharmacokinetics

• The goal of clinical pharmacokinetics is to provide both quantitative relationships between two effects as well as a framework for interpreting drug concentrations through dosage adjustments beneficial to patients.

• The significance lies in enhancing therapeutic efficacy while avoiding undesirable effects by applying principles when selecting or modifying medication regimens.

Key Pharmacokinetic Parameters

• Four main parameters governing drug disposition include:

• Bioavailability: Fraction absorbed into systemic circulation

• Volume of Distribution: Measure space available for containing the drug relative to what remains circulating

• Clearance: Rate at which the body eliminates the drug from circulation

• Half-life: Speed at which a drug is expelled from circulation

• Each parameter will be reviewed individually along with mathematical relationships used to describe plasma accumulation behavior and design dosing regimens based on individual physiological variables.

Elimination Considerations

• When designing rational long-term medication schemes, elimination becomes crucial; maintaining stable concentrations within therapeutic ranges minimizes toxicity risks.

• Assuming complete bioavailability allows achieving steady-state concentrations when elimination rate equals administration rate.

Understanding Drug Elimination Dynamics

The Role of Drug Elimination in Plasma Concentration

• Knowing the desired equilibrium concentration in plasma blood, the drug elimination rate dictates how frequently it should be administered.

Kinetics of Drug Elimination

• The concept of elimination is crucial in pharmacology as its value for a specific drug tends to remain constant within clinically observed concentration ranges.

• Systems responsible for drug elimination, such as metabolizing enzymes and transporters, typically do not saturate; thus, absolute drug elimination rate is primarily a linear function of plasma concentration.

First-order vs. Zero-order Kinetics

• Most drugs are eliminated following first-order kinetics, where a constant fraction of the drug is removed per unit time.

• When elimination mechanisms become saturated, kinetics approach zero-order, where a constant amount of the drug is eliminated per unit time.

Calculating Drug Clearance

• In cases of zero-order kinetics, clearance varies with drug concentration according to the equation: clearance = Vmax / (Km + C), where Km represents the concentration at which half-maximal clearance occurs.

• Clearance is expressed in units of volume/time.

Implications for Pharmacokinetics

• The previous equation parallels Michaelis-Menten kinetics applicable to enzyme activity.

• Developing pharmacokinetic models becomes more complex when elimination deviates from first-order behavior and becomes dependent on medication concentration.

Renal and Hepatic Clearance Mechanisms

• Principles governing drug elimination resemble those seen in renal physiology; for instance, creatinine clearance relates to its metabolic excretion rate versus plasma concentration.

Generalized Drug Elimination Metrics

• At its simplest level, total drug removal can be quantified by normalizing the elimination rate against biological fluid concentrations (e.g., blood or plasma).

Volume-Based Elimination Insights

• It’s essential to note that "elimination" refers not to the quantity removed but rather to the volume of biological fluid from which complete removal would occur (e.g., mL/min/kg).

Organ-Specific Clearance Contributions

• Total body clearance (CLP or systemic clearance based on free drug concentration Cb or Cpoku), reflects additive contributions from organs like kidneys and liver involved in metabolism and excretion.

Factors Affecting Overall Drug Clearance

• Drug elimination may result from processes occurring in various organs including kidneys and liver. Changes in organ function can significantly impact overall calculations—renal insufficiency alters excretion rates for unchanged drugs.

Evaluating Systemic Clearance at Steady State

• Generalized systemic clearance can be assessed under basal equilibrium conditions using mass balance equations.

Example Case Study: Lexapro Excretion Rates

• For example, if 90% of a given medication is excreted intact by a 70 kg male patient with stable renal function, total plasma clearance would equate to approximately 300 mL/min.

Pharmacokinetics and Drug Elimination

Mechanisms of Drug Elimination

• The liver can extract all the drug contained in 120 milliliters of blood every minute, highlighting its efficiency in drug metabolism.

• Despite the liver being the primary organ for elimination, some drugs are removed from plasma at rates that exceed the plasma flow to the liver.

• This discrepancy often occurs because drugs easily distribute into red blood cells (RBC), leading to a higher amount reaching excretion organs than expected based on plasma concentration.

Calculating Drug Elimination

• The relationship between plasma and blood elimination can be calculated using specific equations, allowing for an understanding of how drugs are eliminated from circulation.

• For instance, tacrolimus has a plasma elimination rate nearly double that of hepatic plasma flow but is ultimately eliminated at a much lower rate due to extensive distribution in erythrocytes.

Factors Influencing Drug Metabolism

• After considering tacrolimus's distribution, its actual blood elimination rate is only 63 ml/min, indicating it has low clearance despite high plasma elimination figures.

• In some cases, metabolic disappearance from blood exceeds cardiac output, suggesting extrahepatic metabolism may play a role.

Specific Case Studies: Esmolol and Tacrolimus

• Esmolol's blood elimination rate (11.9 L/min) surpasses cardiac output (5.3 L/min), as it is metabolized by esterases present in RBC.

• Understanding pathological and sociological variables affecting drug elimination requires broader consideration of overall drug clearance mechanisms.

Equations and Extraction Ratios

• The presentation speed of a drug to an organ equals arterial blood flow multiplied by arterial concentration; the exit speed equals venous flow times venous concentration.

• The difference between these rates represents the drug's elimination speed; this can be expressed mathematically to derive extraction ratios useful for modeling therapeutic effects.

Hepatic Drug Clearance Dynamics

• Drugs eliminated via hepatic processes show that their concentration decreases significantly after passing through the liver due to metabolism or excretion into bile.

• When drugs are primarily cleared by the liver, their extraction ratio approaches unity; thus, their removal is limited by hepatic blood flow rather than intrinsic metabolic capacity.

Intrinsic Clearance Considerations

• Some drugs exhibit systemic clearance rates exceeding 6 ml/min/kg due to rapid transport rather than metabolic processes within hepatocytes.

• Additional complexities arise when considering interactions with blood components and tissues which affect calculations related to intrinsic clearance capabilities.

Conclusion on Hepatic Functionality

• Under first-order kinetics conditions, intrinsic clearance measures how effectively an organ can eliminate a drug without limitations imposed by blood flow dynamics.

Understanding Drug Metabolism and Elimination

Key Concepts in Drug Elimination

• When metabolic capacity is low compared to drug presentation speed, elimination correlates directly with the free drug fraction in blood and its intrinsic elimination rate.

• Understanding these concepts aids in interpreting experimental results that may seem questionable.

• For instance, induction of liver disease can affect drug metabolism rates within specific hepatic microsomal systems without altering overall elimination across the organism.

• In drugs with high extraction ratios, blood flow limits elimination; thus, changes due to liver disease induction have minimal impact on overall drug clearance.

• Similarly, for high-extraction drugs, alterations in protein binding due to competition from other drugs have little effect on their elimination.

Renal Elimination Factors

• Changes in intrinsic elimination and protein binding significantly influence the clearance of drugs with reduced intrinsic elimination rates (e.g., warfarin), while blood flow changes minimally affect them.

• The renal elimination process must consider complications related to nephropathy, including alterations in active secretion and reabsorption processes alongside blood flow dynamics.

• A drug's clearance rate depends on glomerular filtration volume and the free concentration of the drug in plasma since only unbound drugs are filtered.

• The secretion rate by kidneys is influenced by intrinsic drug clearance via transporters involved in active secretion, modified by plasma protein binding and transporter saturation levels.

• Additionally, factors affecting tubular reabsorption processes must be considered when evaluating renal drug clearance.

Distribution of Drugs

• Distribution refers to the volume that relates the total amount of a drug present in the body to its concentration in plasma or blood.

• This volume does not necessarily correspond to a physiological space but indicates how much liquid would be needed to contain all the drug at similar concentrations found in plasma.

• It is often perceived as an imaginary volume because many drugs exhibit distribution volumes exceeding known bodily compartments (e.g., chloroquine has a distribution volume near 15,000 L).

• For example, if 500 g of digoxin were present in a 70 kg individual’s body, it would yield an approximate plasma concentration of 0.75 ng/mL—resulting in a calculated distribution volume around 667 L.

• Drugs extensively bound to plasma proteins show distribution volumes similar to plasma levels since most pharmacological analyses measure bound substances effectively.

Variability Influencing Drug Distribution

• Some drugs may have high distribution volumes despite being largely bound to albumin due to sequestration at various sites within tissues.

• The distribution volume varies significantly based on receptor affinity sites' binding characteristics, plasma protein interactions, fat partition coefficients, and accumulation patterns within poorly perfused tissues.

• Patient-specific factors such as age (e.g., water content differences between infants and adults), sex differences (60% for males vs. 55% for females), body composition variations also play crucial roles.

Pharmacokinetics and Drug Distribution

Unique Model of Drug Distribution

• In this unique model, all drug that enters the body goes directly to the central compartment, leading to instantaneous distribution throughout the volume.

• The elimination from this compartment follows first-order kinetics, meaning the amount of drug eliminated per unit time depends on its concentration in the body.

Plasma Concentration Dynamics

• The decrease in plasma concentration over time is described by a specific equation (2-11), where 'k' represents the elimination constant indicating the fraction of drug eliminated per unit time.

• This elimination constant has an inverse relationship with the drug's half-life, expressed as t_1/2 = 0.693/k .

Multi-compartmental Models

• The ideal single compartment model does not fully capture plasma concentration evolution; it must differentiate between tissue deposits and central compartments.

• A multi-compartmental view suggests that well-perfused organs (heart, brain, liver, lungs, kidneys) form a central compartment while less perfused tissues (muscle, skin, fat, bone) act as a final compartment.

Impact of Blood Flow on Drug Distribution

• Variations in blood flow to different tissues can alter drug distribution speeds among them.

• Changes in blood flow may cause some tissues initially considered part of the central volume to equilibrate more slowly and appear only in the final volume during pathological states like cirrhosis.

Systemic Concentrations and Effects

• After rapid intravenous administration, plasma concentrations may be higher in subjects with poor perfusion (e.g., shock), compared to those with adequate blood flow.

• Consequently, high systemic concentrations can lead to intensified effects on well-perfused tissues such as the brain and heart despite overall reduced perfusion levels elsewhere.

Volume of Distribution Concepts

• The concept of multi-compartmental volumes is crucial for understanding drugs that exhibit multiple exponential decay phases during elimination.

• One method for calculating these volumes involves assessing how quickly concentration decreases during final elimination phases using logarithmic curves.

Equilibrium Volume Considerations

• Another important measure is equilibrium volume (BSS), which reflects how drugs distribute at steady state across compartments at equal concentrations relative to measured plasma levels.

Understanding UBSS and Drug Administration

Key Differences in Drug Values

• The value of UBSS (Unbound Blood Serum Concentration) is always greater than that of other measures, indicating a significant advantage in its application.

Impact of Half-Life on Drug Dosage

• The magnitude of the difference between observed half-life during steady-state dosing intervals and terminal half-life will influence drug administration strategies.

Measurement Precision for UBSS

• Accurate measurement of UBSS can only be achieved through intravenous drug administration, highlighting the importance of delivery method.

Steady-State Concentration Dynamics

• Steady-state concentration (CSE) is reached when a drug is administered at a constant rate, as indicated by equation 2-2.

Elimination Rate Equivalence

• At steady state, the elimination rate equals the availability rate of the drug, emphasizing balance in pharmacokinetics.

Dosing Strategies and Pharmacokinetics

Regular vs. Intermittent Dosing

• Regular and intermittent dosing strategies are essential for maintaining effective drug concentrations over time.

Biodisponibility Considerations

• The fractional bioavailability (F), along with dosing intervals (E), plays a crucial role in determining sustained concentrations during continuous intravenous administration.

Average Equilibrium Concentration

• For intermittent dosing, average equilibrium concentration (CSE) reflects the average levels maintained during dosing intervals.

Half-Life Implications in Drug Therapy

Importance of Half-Life Measurements

• Decisions regarding medication dosages rely heavily on understanding half-lives; however, plasma concentrations often follow multi-exponential decay models due to varying body dynamics.

Variability Between Drugs

• Significant differences exist between drugs like gentamicin and indomethacin regarding their terminal half-lives compared to their equilibrium states, affecting therapeutic outcomes.

Elimination Capacity and Its Effects

Relationship Between Elimination and Volume Distribution

• The body's ability to eliminate drugs correlates with both elimination capacity and volume distribution; decreased elimination leads to increased half-life under pathological conditions.

Age-related Changes in Pharmacokinetics

• As individuals age, changes occur not just in elimination but also significantly affect volume distribution impacting overall pharmacokinetics.

Protein Binding Influences on Drug Behavior

Disease Impact on Protein Binding

• Diseases can alter protein binding dynamics within tissues leading to unexpected changes in drug elimination rates rather than volume distribution adjustments.

Understanding Metabolite Formation

Metabolites' Role in Pharmacodynamics

• Sometimes drugs disappear from circulation due to metabolite formation which may have therapeutic or adverse effects; understanding this process is vital for effective treatment planning.

Biodisponibilidad y Metabolismo de Fármacos

Concepto de Biodisponibilidad

• La biodisponibilidad del fármaco se refiere a la fracción que llega a la circulación general tras su administración.

Causas de Absorción Incompleta

• Se mencionan factores como el metabolismo en el epitelio intestinal o hígado, y la excreción biliar, que pueden reducir la cantidad de fármaco activo disponible en el torrente sanguíneo.

Predicción de Disponibilidad Oral

• Conociendo la razón de extracción hepática del medicamento, es posible predecir su disponibilidad oral máxima. Si la eliminación hepática es alta en relación con el flujo sanguíneo, esto resultará en una baja biodisponibilidad tras la ingestión.

Ejemplos Prácticos

• Medicamentos como lidocaína y propranolol muestran cómo la disminución de disponibilidad depende del sitio desde donde se absorbe; cambios en formulaciones no mejorarán esta situación si hay pérdida por primer paso.

Efecto del Metabolismo y Dosis

• La absorción incompleta o metabolismo puede reducir significativamente el valor máximo previsible de un fármaco administrado por vías que sufren pérdida por primer paso. Es crucial incluir el término de biodisponibilidad al calcular dosis efectivas.

Velocidad y Efectos de Absorción

Importancia de la Velocidad de Absorción

• La velocidad a la cual un fármaco alcanza concentraciones plasmáticas influye en su eficacia terapéutica. Una rápida absorción puede resultar en picos altos seguidos por caídas rápidas.

Formulaciones Controladas

• Los preparados con liberación controlada están diseñados para proporcionar una absorción lenta y sostenida, lo que resulta en menos fluctuaciones entre las concentraciones máximas y mínimas durante los intervalos entre dosis.

Variabilidad en Efectos Terapéuticos

• Los efectos deseables e indeseables pueden variar según los sitios donde actúa el fármaco; así, las intensidades relativas pueden cambiar con diferentes ritmos de administración.

Farmacocinética No Lineal

Definición y Causas

• En farmacocinética no lineal, los parámetros como eliminación y volumen de distribución cambian dependiendo de dosis o concentración debido a saturación en unión a proteínas o metabolismo hepático.

Unión Saturable a Proteínas

• Cuando las concentraciones son altas (en órdenes microgramos/ml), se puede observar saturación en sitios de unión a proteínas plasmáticas, afectando así la eliminación del fármaco.

Eliminación Intrínseca Baja

• Si un medicamento tiene baja proporción intrínseca para ser eliminado por el hígado, su semivida puede permanecer constante mientras aumentan las concentraciones plasmáticas debido a saturación.

Predicciones sobre Eliminación

Relación entre Tasa Administrativa y Concentración

• Para medicamentos con alta tasa intrínseca de eliminación, CSS permanece proporcionalmente lineal respecto a la tasa administrativa; esto implica que cambios menores afectan menos su concentración total.

Desafíos Predictivos

• Muchos medicamentos quedan entre extremos predictivos complicados debido a variabilidad inherente al sistema biológico; esto hace difícil anticipar efectos relacionados con unión no lineal a proteínas.

Conclusión sobre Farmacocinética No Lineal

Understanding Non-Linear Pharmacokinetics

Mechanisms of Drug Saturation

• All active mechanisms are saturable, appearing linear at lower drug concentrations, which are significantly less than the saturation point.

• When drug concentration exceeds a certain threshold (kilómetros), a non-linear synergism is observed.

Effects of Metabolism and Transport Saturation

• The main consequences of metabolism or transport saturation differ from those seen with protein binding saturation.

• Protein binding saturation leads to increased centiliters as drug concentration rises, while metabolism or transport saturation decreases centiliters, resulting in an unexpectedly linear synergy under specific concentration limits.

Implications for Drug Administration

• Saturable metabolism results in lower than expected first-pass metabolism after oral administration, leading to higher bioavailability (F).

• As dosing approaches maximum elimination velocity (Vm), the equilibrium concentration increases disproportionately due to the nature of the equations governing these processes.

Understanding Half-Life in Non-Linear Metabolism

• Saturation of metabolism does not affect volume distribution; however, elimination rates decrease as concentration increases until first-order elimination resumes.

• The concept of constant half-life is not applicable to non-linear metabolism within typical clinical concentration ranges.

Challenges in Dosing Adjustments

• Adjusting dosing rates for drugs with non-linear metabolism is complex and unpredictable due to slower equilibrium attainment and disproportionate effects relative to dosage changes.

Case Study: Phenytoin

• Phenytoin serves as an example where metabolic saturation occurs at therapeutic concentration limits, with half-lives varying between 6 to 24 hours.

• Therapeutic levels range from 5 to 10 mg/L near the lower limit and up to 10–20 mg/L at the upper limit.

Considerations for Pediatric Patients

• In young children or those recently treated with urgent anticonvulsants, concentrations can drop significantly (e.g., down to 1 mg/L).

Dosage Calculations and Outcomes

• For adults aiming for a desired phenytoin level of 15 mg/L via a daily dose of 300 mg, calculations indicate that adjustments must be precise due to steep pharmacokinetic curves.

Precision in Dosing

• A dosage reduction by just 10% can lead to suboptimal plasma levels (e.g., CSS dropping below desired values).

Risk Management in Dosing

• Conversely, increasing doses may lead to slow but steady rises in plasma concentrations that could result in adverse effects over time.

Therapeutic Index Considerations

• For drugs like phenytoin with narrow therapeutic indices exhibiting non-linear kinetics, monitoring plasma concentrations becomes crucial for effective treatment without toxicity risks.

Special Attention Required for Vulnerable Populations

• This monitoring is especially important for newborn patients where adverse effects may be difficult to detect early on.

Consultation Recommendations

Importance of Specialist Consultation

• It’s advisable to consult specialists regarding pharmacokinetics when managing such cases effectively.

Design and Optimization

• Focus on designing optimal dosing regimens based on individual patient needs.

Pharmacodynamics Overview

Concentration Dependence

• The intensity of drug effects correlates directly with its concentration above minimum effective levels.

Duration vs. Effectiveness

• The duration reflects how long concentrations remain above this threshold.

Therapeutic Window Insights

• Both desired and adverse effects fall within a therapeutic window defined by effective versus toxic concentrations.

Multiple Doses Impact

• After multiple doses during prolonged treatments, understanding frequency and quantity becomes essential for achieving optimal therapeutic outcomes.

Defining Therapeutic Limits

Dosing Strategies and Therapeutic Ranges

Understanding Drug Concentration Limits

• For certain medications, the upper limit of the therapeutic range should not exceed double the lower limit.

• Variability in patient responses can occur; some may require higher concentrations than the therapeutic range for efficacy, while others may experience side effects at much lower doses.

Example: Digoxin and Dosing Adjustments

• Digoxin is cited as an example where careful dosing is crucial.

• The method of trial and error can be used to optimize dosage, but challenges arise regarding how frequently to adjust doses and by what magnitude.

Empirical Rules for Dose Adjustment

• A practical rule suggests not changing medication doses by more than 50% or adjusting them more frequently than every 3 to 4 half-lives.

• Some agents have a dose-toxicity relationship that necessitates maximizing efficacy while minimizing toxicity.

Managing Toxicity Risks

• In many drugs, measuring effects can be difficult; thus, there’s a risk of toxicity or ineffectiveness due to narrow therapeutic indices.

• Careful dose adjustments are essential, often limited by toxic effects rather than efficacy.

Goals of Therapeutic Dosing

• The primary therapeutic goal is to maintain drug levels within the therapeutic range.

• For most drugs, specific concentration limits are not identified or necessary; understanding general relationships between concentration and effect suffices.

Narrow Therapeutic Index Drugs

• A small number of drugs (e.g., digoxin, aminoglycosides) have closely spaced effective and toxic concentrations.

• For these drugs, establishing a target plasma concentration that balances efficacy with minimal toxicity is reasonable.

Practical Application in Clinical Settings

• After initial dosing based on calculated targets, drug levels should be measured regularly for adjustments.

• Most clinical situations involve administering repeated doses or continuous IV infusion to maintain steady-state concentrations linked with therapeutic ranges.

Calculating Maintenance Doses

• The fundamental objective is determining an appropriate maintenance dose to sustain desired plasma concentrations.

• This involves adjusting administration rates so that drug input equals elimination rates based on established equations.

Case Study: Digoxin in Heart Failure Management

• In heart failure cases, achieving a target plasma concentration of 0.7 ng/mL within a specified range is critical.

• Using pharmacokinetic data allows calculation of dosages needed to reach this equilibrium state effectively.

Monitoring Patient Response

• Regular monitoring is vital as variations in tablet sizes can limit dosing accuracy; intermediate-sized tablets may be required for better management.

Interval Between Doses and Pharmacokinetics

Understanding Dose Intervals in Medication Administration

• The interval between doses is crucial when administering medication intermittently.

• Large fluctuations in drug concentrations are generally not harmful if managed through appropriate dosing intervals.

• If absorption and distribution were instantaneous, concentration fluctuations would depend solely on the drug's elimination half-life.

• Choosing a dosing interval equal to the half-life results in a total fluctuation of double, which is typically acceptable.

• Pharmacodynamic considerations can modify this situation.

Therapeutic Concentrations and Dosing Strategies

• When therapeutic concentrations exceed necessary levels, maximum dose limits should be established, potentially extending the dosing interval beyond the elimination half-life for convenience.

• Moxicillin has a half-life of nearly two hours; however, administering it every two hours may not be practical.

• Instead, larger doses are often given every eight to twelve hours to maintain effective levels.

Calculating Steady-State Concentrations

• It is essential to calculate maximum and minimum concentrations that will arise with specific dosing intervals.

• The minimum steady-state concentration (CSS,min) can be reasonably calculated using equation 2-19: CSS,min = (dose / Vd * F), where F represents bioavailability and Vd is volume of distribution.

• The term "ex kilotones" refers to the fraction of the last dose corrected for availability that remains in the body at the end of an interval.

Complex Drug Dynamics

• For drugs with multi-exponential pharmacokinetics administered orally, calculating maximum steady-state concentration (CSS,max) requires complex constants related to distribution and absorption.

• Omitting these terms simplifies calculations but may lead to overestimating CSS,max using equation 2-20 as an approximation.

Example Case Study: Digoxin Administration

• In patients with congestive heart failure, a maintenance dose of 0.125 mg digoxin every 24 hours was estimated to achieve an average plasma concentration of 0.78 ng/mL during intervals between doses.

• This concentration is typically effective with minimal toxicity; understanding maximum and minimum plasma concentrations under this regimen is critical for safety.

Volume Distribution Calculations

• To determine plasma concentrations accurately, one must calculate digoxin's volume of distribution based on available pharmacokinetic data (see Appendix 2).

Implications for Patient Compliance

• While theoretical calculations suggest stable plasma levels, practical adherence issues arise; dosages must align with patient routines—administering every third day can complicate compliance among certain populations.

Disadvantages of Saturation Doses

Risks and Considerations

• The use of saturation doses presents significant disadvantages.

• There is a risk of exposing susceptible individuals to toxic concentrations unexpectedly.

• If the drug has a long half-life, it requires an extended period for concentration to decrease when levels become excessive.

• Saturation doses are typically large and often administered rapidly via parenteral routes, which can be particularly dangerous.

• Toxic effects may arise from the drug acting on sites that equilibrate quickly with plasma.

Administration Strategies

• Initial saturation doses calculated based on NBS are limited within the initial central distribution volume after drug distribution.

• It is generally advisable to divide the initial saturation dose into smaller fractions administered over a predetermined time frame.

• An alternative approach involves providing the initial dose through continuous intravenous infusion over a set duration.

• Ideally, dosing should be exponentially increasing to reflect concurrent accumulation with maintenance dosing, achievable using computerized drip pumps.

Example of Dosage Strategy

Dosage Calculation

• Maintenance should last at least 12 days based on a half-life of 3.1 days.

• A specific ideal separation of 0.9 ng/mL is chosen, below the maximum recommended level of 1.0 ng/mL.

Initial Oral Dose

• The initial oral dose should be 0.25 mg followed by another 0.25 mg every 6 to 8 hours, monitoring closely for patient response before administering a final dose of 0.125 mg after 12 to 14 hours.

Individualization in Dosing

Importance of Personalization

• Individualizing dosage regimens is crucial for establishing rational pharmacological patterns; knowledge about F (centiliters), DSSI-I (Drug Sensitivity Index), and absorption rates is necessary.

Variability in Patient Response

• Recommended dosing schemes are often designed for average patients but fail to account for significant interindividual variability in pharmacokinetic parameters and responses.

Therapeutic Monitoring

Adjusting Dosages Based on Concentration

• Individualized dosing regimens aim to achieve desired efficacy while minimizing adverse effects; measuring plasma concentrations can provide valuable data for adjusting dosages during treatment.

Therapeutic Drug Monitoring Challenges

• In situations where therapeutic drug monitoring is possible, correlating results with therapeutic ranges enhances understanding and allows better adjustments based on blood concentration measurements.

Practical Considerations in Measurement

Timing and Methodology

• Practical details regarding measurement timing are critical; samples must be taken at precise moments between doses if intermittent dosing is used.

Understanding Measured Concentrations

• Drug concentrations measured at any point during intervals provide insights into potential toxicity but come with challenges due to variability among patients' sensitivity to drugs.

Clinical Interpretation

Understanding Drug Concentrations and Dosing

Importance of Timing in Sample Collection

• Digoxin concentrations often exceed potentially toxic levels shortly after oral doses, although these peak levels do not necessarily indicate toxicity before maximum effects are reached.

• Collecting drug concentration samples immediately post-administration can lead to confusion, as they provide little useful information regarding the drug's efficacy or safety.

• The goal of obtaining samples during a supposed equilibrium state is to refine calculations for dosing adjustments.

• Early concentrations reflect absorption rates rather than elimination, which are less relevant for long-term maintenance dosing decisions.

• For dose adjustments, samples should ideally be taken just before the next planned dose when concentrations are at their minimum.

Exceptions and Special Considerations

• Some drugs may be nearly eliminated between doses, necessitating early sample collection if there’s uncertainty about achieving effective concentrations.

• In cases of renal insufficiency where drug accumulation is a concern, measuring pre-dose concentrations can indicate whether accumulation has occurred and is more informative than peak concentration values.

• It is advisable to measure both maximum and minimum concentrations to gain a comprehensive understanding of the drug's behavior in patients over time.

Establishing Steady-State Conditions

• A critical aspect when obtaining samples relates to establishing a steady-state condition based on maintenance dosing regimens.

• Steady-state equilibrium typically occurs after four half-lives have passed with constant dosing.

• Samples taken too soon after starting treatment may not accurately reflect true elimination or steady-state conditions.

• Delaying sample collection until steady-state could result in potential harm from toxic drugs if damage has already occurred by that point.

Guidelines for Sample Collection

• Simple guidelines can help ensure proper monitoring of drug concentrations throughout treatment plans.

• Initial samples should be collected after two calculated half-lives assuming no loading doses were given.

• If initial concentration exceeds 90% of expected steady-state levels, dosage should be halved; subsequent samples should follow similar timing protocols for further adjustments.

Adjustments Based on Concentration Measurements

• If initial measurements are acceptable but below expectations, physicians typically wait another two half-lives before adjusting dosages accordingly.

• Intermittent dosing presents unique challenges regarding optimal timing for sample collection to assess drug concentration effectively.

• Samples obtained right before the next dose will show minimum rather than average concentrations but can still inform dosage adjustments through calculations based on established equations.

Calculating Average Concentrations

• For first-order kinetics drugs, relationships exist among average, minimum, and maximum concentrations at steady state that correlate linearly with administered dosages.

• To adjust dosages effectively, one can use ratios between measured and target concentrations aligned with available dosage magnitudes.

• For example: if a patient receiving digoxin shows an equilibrium concentration of 0.35 ng/mL instead of the expected 0.7 ng/mL, increasing daily dosage from 0.125 mg to 0.25 mg would be appropriate.

• This adjustment reflects necessary changes based on observed pharmacokinetics while ensuring therapeutic effectiveness.

Challenges in Chronic Disease Treatment Adherence

Overview of Treatment Adherence Issues

• The treatment of chronic diseases with antihypertensives, antiretrovirals, and anticoagulants presents significant challenges related to therapeutic adherence.

• Without special efforts to address adherence issues, only about 50% of patients follow their prescribed treatment plans satisfactorily. Approximately 33% exhibit partial adherence, while around one in six patients completely fails to comply with medical orders (Babaktoon & Bangalore, 2009).

• The issue of missed doses is more prevalent than that of excessive dosing among patients.